Pharmaceuticals News and Research

RSS

Rexahn completes 33% of 300 patient enrollment in Serdaxin Phase IIb clinical trial for major depressive disorder

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has enrolled 33 percent of the total projected patients required for its Phase IIb clinical trial of Serdaxin to treat major depressive disorder (MDD).

24 Mar 2011

ISEFC, TB Alliance to establish Global Health R&D Center of China

The International Scientific Exchange Foundation of China, a technical public foundation dedicated to promoting and advancing scientific development, cooperation, and exchange, today signed a Memorandum of Understanding with the Global Alliance for TB Drug Development, to work together to establish the Global Health R&D Center of China, a world-class organization focused on developing innovative new treatments for public health diseases, including tuberculosis, malaria, and HIV/AIDS.

24 Mar 2011

Oramed reports successful completion of ORMD-0801 oral insulin toxicity study

Oramed Pharmaceuticals Inc., a developer of oral delivery systems, announced today that it has successfully completed a comprehensive toxicity study for its flagship oral insulin capsule, ORMD-0801.

24 Mar 2011

KaloBios commences KB004 Phase 1 trial in patients with leukemia

KaloBios Pharmaceuticals, Inc., a privately held biopharmaceutical company, today announced treatment of the first patient in a Phase 1 clinical trial of KB004, its first-in-class Humaneered™ monoclonal antibody, in EphA3-expressing hematologic malignancies.

24 Mar 2011

Cell receptor recycling mechanism discovery opens up new class of therapeutic targets

Prof. Manojkumar Puthenveedu of Carnegie Mellon University studies the mechanisms by which membrane trafficking controls and co-ordinates the complex signalling pathways in the brain. Despite the fact that almost all diseases can be traced to a defect in how cells respond to signals, little is known about how signalling pathways are maintained in normal cells and the changes that occur in abnormal conditions.

23 Mar 2011

Cilag, POZEN enter license agreement to develop and commercialize MT 400

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced that it has entered into a license agreement with Cilag GmbH International, a division of Johnson & Johnson, for the development and commercialization of MT 400 in Brazil, Colombia, Ecuador and Peru.

23 Mar 2011

Positive data from Omeros' OMS302 Phase 2b trial in patients undergoing cataract surgery

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today reported positive data from a Phase 2b clinical trial evaluating OMS302 in patients undergoing cataract surgery.

23 Mar 2011

Xenon founder receives Canada Wightman Award for leadership in medical science

Dr. Michael Hayden, a Xenon founder and Chief Scientific Officer, has received the Canada Gairdner Wightman Award for leadership in medical science in Canada.

23 Mar 2011

Japanese, International officials continue to monitor radiation levels

Japanese officials plan to measure radiation levels in the ocean beyond the country's borders on Tuesday and Wednesday, the International Atomic Energy Agency said, CNN reports.

23 Mar 2011

Spectrum's Prior Approval Supplement for Indium-111 ZEVALIN accepted for review by FDA

Spectrum Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the Prior Approval Supplement containing data providing for the removal of the Indium-111 ZEVALIN® (ibritumomab tiuxetan) pre-treatment imaging evaluation, more commonly referred to as the "bioscan" requirement.

23 Mar 2011

Opinions: Counterfeit medicines; oral rehydration therapy in Bangladesh; increasing access to safe drinking water; attracting R&D for health issues in Latin America

"The Obama administration and Congress should continue efforts to strengthen the safety of America's drug supply and, simultaneously, coordinate a global response to the problem of counterfeit drugs," Thomas Kubic, president & CEO of the Pharmaceutical Security Institute and a former deputy assistant director at the FBI, writes in a post on The Hill's "Congress Blog," where he describes the health risks associated with such drugs.

23 Mar 2011

PRWP receives two new patents for Galectin-targeting compounds in the U.S., Australia

Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that the Company has been granted two new patents, "Co-administration of a Polysaccharide with a Chemotherapeutic Agent for the Treatment of Cancer" in Australia and "Selectively Depolymerized Galactomannan Polysaccharide" in the United States.

23 Mar 2011

SGEN, Abbott enter collaboration agreement for ADC products

Seattle Genetics, Inc.today announced that it has entered into a collaboration agreement with Abbott under which Abbott will pay an upfront fee of $8 million for rights to utilize Seattle Genetics' antibody-drug conjugate technology with antibodies to a single oncology target.

23 Mar 2011

POZEN files motion for Treximet patent litigation against Par

POZEN Inc., a pharmaceutical company committed to transforming medicines that transform lives, today announced that it has filed a motion for a preliminary injunction seeking to prevent Par Pharmaceuticals, Inc. from launching a generic version of Treximet.

23 Mar 2011

Genetic errors in women linked to increased risk of preeclampsia

Scientists have identified genetic errors in women with autoimmune diseases that increase the risk of preeclampsia, a potentially life-threatening condition that occurs in 10 percent of all pregnancies.

23 Mar 2011

UDL enters license agreement with Humeca for burn, wound care products

Mylan Inc. today announced that its subsidiary UDL Laboratories, part of the Mylan Institutional business, has entered a license agreement with Humeca, a leading plastic surgery and burn treatment products company, for the exclusive U.S. distribution rights of Humeca products.

23 Mar 2011

NeoTract initiates patient enrollment for UroLift System trial to treat prostrate cancer

NeoTract, Inc. a medical device company focused on developing urology devices, today announced that the first U.S. patients have been enrolled in a multinational trial of its UroLift® System at Western Urological Clinic in Salt Lake City, Utah.

23 Mar 2011

SMR, RTU enter license agreement for RESCULA eye drops

Sucampo Pharmaceuticals, Inc. today announced that its wholly owned subsidiary, Sucampo Manufacturing & Research AG, and R-Tech Ueno, Ltd., a pharmaceutical company founded in Japan in 1989, have entered into a license agreement for RESCULA eye drops, expanding Sucampo's rights beyond its previously agreed territory of the United States and Canada to all countries in Europe and the rest of the world except Japan, Korea, Taiwan and the People's Republic of China.

23 Mar 2011

Positive results from TheraVida THVD-201 Phase 1 trial in patients with OAB, UUI

TheraVida, Inc., a clinical stage biopharmaceutical company developing novel combination drug products, today presented positive results from a Phase 1 clinical trial of its lead product candidate THVD-201 for the treatment of overactive bladder and urge urinary incontinence.

23 Mar 2011

EMD Millipore to acquire Biotest microbiology business to expand product portfolio

EMD Millipore, the Life Science division of Merck KGaA of Germany, today announced plans to expand its industrial microbiological testing portfolio. This follows Merck KGaA's announcement it has entered into a definitive agreement to acquire the microbiology business of Germany-based Biotest AG.

22 Mar 2011

Pharmaceuticals News and Research

Rexahn completes 33% of 300 patient enrollment in Serdaxin Phase IIb clinical trial for major depressive disorder

ISEFC, TB Alliance to establish Global Health R&D Center of China

Oramed reports successful completion of ORMD-0801 oral insulin toxicity study

KaloBios commences KB004 Phase 1 trial in patients with leukemia

Cell receptor recycling mechanism discovery opens up new class of therapeutic targets

Cilag, POZEN enter license agreement to develop and commercialize MT 400

Positive data from Omeros' OMS302 Phase 2b trial in patients undergoing cataract surgery

Xenon founder receives Canada Wightman Award for leadership in medical science

Japanese, International officials continue to monitor radiation levels

Spectrum's Prior Approval Supplement for Indium-111 ZEVALIN accepted for review by FDA

Opinions: Counterfeit medicines; oral rehydration therapy in Bangladesh; increasing access to safe drinking water; attracting R&D for health issues in Latin America

PRWP receives two new patents for Galectin-targeting compounds in the U.S., Australia

SGEN, Abbott enter collaboration agreement for ADC products

POZEN files motion for Treximet patent litigation against Par

Genetic errors in women linked to increased risk of preeclampsia

UDL enters license agreement with Humeca for burn, wound care products

NeoTract initiates patient enrollment for UroLift System trial to treat prostrate cancer

SMR, RTU enter license agreement for RESCULA eye drops

Positive results from TheraVida THVD-201 Phase 1 trial in patients with OAB, UUI

EMD Millipore to acquire Biotest microbiology business to expand product portfolio

Industry Focus - Biopharma eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence